Drug Safety

      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA?

      Pre

      David Liew drdavidliew

      3 months ago
      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA? Pretty good so far - but obviously will be under enormous scrutiny when we are looking at diseases with good existing therapies #ACR25 ABST0471 @RheumNow https://t.co/xXyzOwLvx8
      Another toxicity signal to watch in the CAR T space: LICATs
      Abstract 1537 reports a new immune-related toxicity distinct

      Akhil Sood MD, MS AkhilSoodMD

      3 months ago
      Another toxicity signal to watch in the CAR T space: LICATs Abstract 1537 reports a new immune-related toxicity distinct from CRS or ICANS: 🔹Affects organs prev involved in autoimmune dx: skin (35%) and kidneys (22%) 🔹Mostly mild (Grade 1–2); 3 cases Grade 3 @RheumNow #ACR25 https://t.co/mtZh47nWtv
      CAR-T toxicity in hematology
      (the things we have to look out for in rheumatology, as application of CAR-T potentially br

      David Liew drdavidliew

      3 months ago
      CAR-T toxicity in hematology (the things we have to look out for in rheumatology, as application of CAR-T potentially broadens) @andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/1YjadL7LCF
      #Urinary #biomarkers #lupus #nephritis
      #Tenascin C -suggests repair, fibrosis, progress of #LN
      #IL16, #CD163, & mor

      Janet Pope Janetbirdope

      3 months ago
      #Urinary #biomarkers #lupus #nephritis #Tenascin C -suggests repair, fibrosis, progress of #LN #IL16, #CD163, & more for LN activity Sometime a biomarker may replace repeat #kidney #biopsies? #AMP group #Accelerated #Medicines #Program #ACR24 @ACRheum @RheumNow abst#851
      #GCA & #PMR @ACRheum #ACR25
      #gamechangers #ACRBest
      Yr 2 Select-GCA abst#776
      #upadacitinib in yr2 of GCA REDUCES flar

      Janet Pope Janetbirdope

      3 months ago
      #GCA & #PMR @ACRheum #ACR25 #gamechangers #ACRBest Yr 2 Select-GCA abst#776 #upadacitinib in yr2 of GCA REDUCES flares HELPFUL info ?ability to get drug for 2 yrs hopefully Failed Phase3 RCT of #secukinumab in #GCA helped #PMR abst#1175 & +Ph3 for PMR REPLENISH RCT @RheumNow https://t.co/5lH6HXhnfg
      When should you order a renal bx in suspected #LN?

      Active urinary sediment
      Used to be #UPCR 500g/g or more
      Abst#772 loo

      Janet Pope Janetbirdope

      3 months ago
      When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more Abst#772 looked at UPCR 250g/g to 499 71% + LN and half needed Rx esp if Low C3,C4 Black race Petri, Baltimore #lupus #cohort #ACR25 @ACRheum @RheumNow
      psoriasis,arms,pain
      IL-23 Blockade Goes Oral
      3 months ago
      A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
      eyes
      Sjogren’s disease: two drugs with positive trials
      3 months ago
      After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost! At this year’s ACR25 Convergence Conference in Chicago, not one but two drugs presented their efficacy and safety data in patients with moderate to severe disease activity as defined by ESSDAI score ≥ 5 points.
      Phase 1 study of CAR-Treg in difficult to treat RA

      4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required &am

      Mike Putman EBRheum

      3 months ago
      Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD"
      -

      Mike Putman EBRheum

      3 months ago
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD" - Gregory McDermott (Epi Abstracts, #2662) Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising @RheumNow
      Excited about this target trial emulation in RA-ILD

      Compared to RTX, NO significant difference in hospitalization/trans

      Mike Putman EBRheum

      3 months ago
      Excited about this target trial emulation in RA-ILD Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF Trends toward ABA and JAK looking better than RTX Need trials for sure, but I like this project a lot @RheumNow #ACR25 https://t.co/FQcphRvyHK
      #2662
      Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi
      N

      Mrinalini Dey DrMiniDey

      3 months ago
      #2662 Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD @RheumNow #ACR25
      McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen i

      Richard Conway RichardPAConway

      3 months ago
      McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest https://t.co/ghHEKztvgz
      #PD1 Ab looks good and safe in active RA

      Rosnilimab, a Selective and Potent Depleter of Pathogenic T

      Many failed sever

      Janet Pope Janetbirdope

      3 months ago
      #PD1 Ab looks good and safe in active RA Rosnilimab, a Selective and Potent Depleter of Pathogenic T Many failed several Rx already No safety signals compared to another PD1i Proof of benefit in biospecimens too! abst#LB19 #ACR25 @RheumNow @ACRheum #ACRBest https://t.co/TmEOCfuHZU
      TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation):
      🔹Higher total renal response w/ TAC + MMF + GC a

      Akhil Sood MD, MS AkhilSoodMD

      3 months ago
      TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X

      Podcasts

      • ACR 2025 Daily Podcasts Day2d

      Catch up on Conference Podcasts

      ×